Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor XIII (FXIII) and angiogenesis.

R Dardik1, J Loscalzo, A Inbal

  • 1Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.

Journal of Thrombosis and Haemostasis : JTH
|September 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma.

Clinical pharmacology and therapeutics·2019
Same author

Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Current strategy for genetic analysis of haemophilia A families.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Pharmacokinetic profile of Optivate® (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Wound 'dechronification' with negatively-charged polystyrene microspheres: a double-blind RCT.

Journal of wound care·2013

Factor XIII (FXIII) is crucial for blood clot formation and also promotes new blood vessel growth (angiogenesis). This review explores FXIII's pro-angiogenic effects in tissue repair and remodeling.

Area of Science:

  • Biochemistry
  • Hematology
  • Cell Biology

Background:

  • Factor XIII (FXIII) is a plasma transglutaminase essential for stabilizing fibrin clots during coagulation.
  • Beyond hemostasis, FXIII is implicated in wound healing and embryo implantation, processes involving angiogenesis.

Purpose of the Study:

  • To review the role of Factor XIII in angiogenesis.
  • To elucidate the molecular mechanisms behind FXIII's pro-angiogenic effects.

Main Methods:

  • Literature review of studies on Factor XIII and angiogenesis.
  • Analysis of molecular pathways involved in FXIII-mediated angiogenesis.

Main Results:

  • Thrombin-activated FXIII (FXIIIa) cross-links fibrin, maturing blood clots.

Related Experiment Videos

  • FXIII exhibits pro-angiogenic activity, contributing to tissue repair and remodeling.

    • Conclusions:

    • Factor XIII plays a significant role in angiogenesis.
    • FXIII's pro-angiogenic function is a key contributor to its role in tissue repair.